Research Progress of Male Breast Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 DENGFeng , ADILIJIANG·Maimaitiming , LUANMei-xiang ,  DILIMULATI·Aisimutula

Department of Breast Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, Xinjiang Uygur Autonomous Region, China;

Corresponding author：

DILIMULATI·Aisimutula, Email: 2499156828@qq.com

Keywords：

Male breast cancer; Risk factors; Treatment

DOI：

10.7507/1007-9424.20160387

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the research progress of the cause, treatment, and other aspects in male breast cancer (MBC). Methods Through reading the related literatures, relevant literatures of MBC were reviewed. Results Family history, BRCA1/2 mutation, the imbalance of level of estrogen and androgen, and other factors were risk factors of the MBC. Sentinel lymph node biopsy (SLNB) was feasible in the MBC. Radiotherapy could control local recurrence of MBC, and chemotherapy may be beneficial for long-term survival rate of MBC. The endocrine therapy principle for MBC was not exact as female breast cancer (FBC). Conclusions MBC has many risk factors. Radiotherapy, chemotherapy, and endocrine therapy are benefit to MBC patients, but it still needs to be confirmed by many high-quality clinical researches of large sample.

Citation： DENGFeng, ADILIJIANG·Maimaitiming, LUANMei-xiang, DILIMULATI·Aisimutula. Research Progress of Male Breast Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2016, 23(12): 1538-1543. doi: 10.7507/1007-9424.20160387 Copy

1.	Ruddy KJ, Winer EP. Male breast cancer:risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol, 2013, 24(6):1434-1443.
2.	Ly D, Forman D, Ferlay J, et al. An international comparison of male and female breast cancer incidence rates. Int J Cancer, 2013, 132(8):1918-1926.
3.	程兆明, 蒋光愉, 曾颖, 等. 217077名妇女乳腺癌筛查结果分析.中华普通外科杂志, 2016, 31(4):328-332.
4.	Korde LA, Zujewski JA, Kamin L, et al. Multidisciplinary meeting on male breast cancer:summary and research recommendations. J Clin Oncol, 2010, 28(12):2114-2122.
5.	Serarslan A, Gursel B, Okumus NO, et al. Male breast cancer:20 years experience of a tertiary hospital from the middle black sea region of Turkey. Asian Pac J Cancer Prev, 2015, 16(15):6673-6679.
6.	Chavez-Macgregor M, Clarke CA, Lichtensztajn D, et al. Male breast cancer according to tumor subtype and race a population-based study. Cancer, 2013, 119(9):1611-1617.
7.	Dawood S. Updates from the 2014 San antonio breast cancer symposium. Indian J Med Paediatr Oncol, 2015, 36(1):66-70.
8.	Johansson I, Killander F, Linderholm B, et al. Molecular profiling of male breast cancer-lost in translation. Int J Biochem Cell Biol, 2014, 53:526-535.
9.	Korde LA, Zujewski JA, Kamin L, et al. Multidisciplinary meeting on male breast cancer:summary and research recommmendations. J Clin Oncol, 2010, 28(12):2114-2122.
10.	De Juan I, Palanca S, Domenech A, et al. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study. Fam Cancer, 2015, 14(4):505-513.
11.	Silvestri V, Barrowdale D, Mulligan AM, et al. Male breast cancer in BRCA1 and BRCA2 mutation carriers:pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res, 2016, 18(1):15.
12.	Brinton LA, Cook MB, McCormack V, et al. Anthropometric and hormonal risk factors for male breast cancer:male breast cancer pooling project results. J Natl Cancer Inst, 2014, 106(3):djt465.
13.	Humphries MP, Jordan VC, Speirs V. Obesity and male breast cancer:provocative parallels. BMC Med, 2015, 13:134.
14.	Brinton LA, Key TJ, Kolonel LN, et al. Prediagnostic sex steroid hormones in relation to male breast cancer risk. J Clin Oncol, 2015, 33(18):2041-2050.
15.	Grundy A, Harris SA, Demers PA, et al. Occupational exposure to magnetic fields and breast cancer among Canadian men. Cancer Med, 2016, 5(3):586-596.
16.	Morrogh M, King TA. The significance of nipple discharge of the male breast. Breast J, 2009, 15(6):632-638.
17.	Gradishar WJ, Anderson BO, Balassanian R, et al. Breast cancer version 2.2015. J Natl Compr Canc Netw, 2015, 13(4):448-475.
18.	Graspari E, Ricci A, Liberto V, et al. An unusual case of mammary paget's disease diagnosed using dynamic contrast-enhanced MRI. Case Rep Radiol, 2013, 2013:206235.
19.	刘新丽, 刘芳芳, 郑屹, 等.男性乳腺癌临床病理特征及预后分析.中国肿瘤临床, 2014, 41(23):1521-1526.
20.	王翔宇, 方仪, 杨雪, 等.男性乳腺癌的临床病理特征及生存分析.临床肿瘤学杂志, 2016, 21(4):340-343.
21.	Nilsson C, Koliadi A, Johansson I, et al. High proliferation is associated with inferior outcome in male breast cancer patients. Mod Pathol, 2013, 26(1):87-94.
22.	马家芳, 乔昱, 丁丽, 等.男性乳腺癌患者临床病理特征及诊治分析.中华老年医学杂志, 2015, 34(7):790-792.
23.	Leone JP, Leone J, Zwenger AO, et al. Prognostic significance of tumor subtypes in male breast cancer:a population-based study. Breast Cancer Res Treat, 2015, 152(3):601-609.
24.	张志刚, 郭团魁, 周玉峰.男性乳腺癌临床病例分析.疾病监测与控制, 2016, 10(4):336-338.
25.	韩娜, 王晓稼. 29例男性乳腺癌临床分析.分子诊断与治疗杂志, 2016, 8(1):23-26.
26.	Abreu MH, Afonso N, Abreu PH, et al. Male breast cancer:looking for better prognostic subgroups. Breast, 2016, 26:18-24.
27.	Zhou FF, Xia LP, Guo GF, et al. Changes in therapeutic strategies in Chinese male patients with breast cancer:40 years of experience in a single institute. Breast, 2010, 19(6):450-455.
28.	李林, 朱明智, 邱新光.男性乳腺癌前哨淋巴结活检11例分析.国际外科学杂志, 2015, 42(3):171-173.
29.	Maráz R, Boross G, Pap-Szekeres J, et al. The role of sentinel node biopsy in male breast cancer. Breast Cancer, 2016, 23(1):85-91.
30.	Gnerlich JL, Deshpande AD, Jeffe DB, et al. Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration. Ann Surg Oncol, 2011, 18(17):1837-1844.
31.	Zaenger D, Rabatic BM, Dasher B, et al. Is breast conserving therapy a safe modality for early-stage male breast cancer. Clin Breast Cancer, 2016, 16(2):101-104.
32.	Bratman SV, Kapp DS, Horst KC. Evolving trends in the initial locoregional management of male breast cancer. Breast, 2012, 21(3):296-302.
33.	Atalay C, Kanlioz M, Altinok M. Prognostic factors affecting survival in male breast cancer. J Exp Clin Cancer Res, 2003, 22(1):29-33.
34.	Yu E, Suzuki H, Younus J, et al. The impact of post-mastectomy radiation therapy on male breast cancer patients-a case series. Int J Radiat Oncol Biol Phys, 2012, 82(2):696-700.
35.	Cutuli B, Le-Nir CC, Serin D, et al. Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Crit Rev Oncol Hematol, 2010, 73(3):246-254.
36.	Giordano SH, Perkins GH, Broglio K, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer, 2005, 104(11):2359-2364.
37.	Sun B, Zhang LN, Zhang J, et al. The prognostic value of clinical and pathologic features in nonmetastatic operable male breast cancer. Asian J Androl, 2016, 18(1):90-95.
38.	Untch M, Gerber B, Harbeck N, et al. 13th st. Gallen international breast cancer conference 2013:primary therapy of early breast cancer evidence, controversies, consensus-opinion of a german team of experts (zurich 2013). Breast Care (Basel), 2013, 8(3):221-229.
39.	王丽娜, 严颖, 李惠平, 等.男性乳腺癌25例的临床病理特征及生存分析.癌症进展, 2014, 12(1):64-69.
40.	Sousa B, Moser E, Cardoso F. An update on male breast cancer and future directions for research and treatment. Eur J Pharmacol, 2013, 717(1-3):71-83.
41.	Zhou FF, Xia LP, Wang X, et al. Analysis of prognostic factors in male breast cancer:a report of 72 cases from a single institution. Chin J Cancer, 2010, 29(2):184-188.
42.	Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med, 2002, 137(8):678-687.
43.	Xu S, Yang Y, Tao W, et al. Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. Breast Cancer Res Treat, 2012, 136(2):495-502.
44.	Wenhui Z, Shuo L, Dabei T, et al. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment. Eur J Endocrinol, 2014, 171(4):527-533.
45.	Eggemann H, Ignatov A, Smith BJ, et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat, 2013, 137(2):465-470.
46.	Pemmaraju N, Munsell MF, Hortobagyi GN, et al. Retrospective review of male breast cancer patients:analysis of tamoxifen-related side-effects. Ann Oncol, 2012, 23(6):1471-1474.
47.	刘朋, 王芙荣, 纪立伟, 等. 212例他莫昔芬不良反应回顾性分析.中国药物应用与监测, 2011, 8(6):366-368.
48.	Di Lauro L, Vici P, Del Medico P, et al. Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. Breast Cancer Res Treat, 2013, 141(1):119-123.
49.	Doyen J, Italiano A, Largillier R, et al. Aromatase inhibition in male breast cancer patients:biological and clinical implications. Ann Oncol, 2010, 21(6):1243-1245.
50.	陈峰, 邱丽贞.芳香化酶抑制剂在早期男性乳腺癌治疗中的生物学效益及临床意义.中华医学杂志, 2014, 94(4):273-275.
51.	Pritchard KI, Shepherd LE, Chapman J, et al. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women:NCIC CTG Ma.14. J Clin Oncol, 2011, 29(29):3869-3876.
52.	Kuba S, Ishida M, Oikawa M, et al. Aromatase inhibitors with or without luteinizing hormone-releasing hormone agonist for metastatic male breast cancer:report of four cases and review of the literature. Breast Cancer, 2016, [Epub ahead of print].
53.	Zagouri F, Sergentanis TN, Koutoulidis V, et al. Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer:a case series. Br J Cancer, 2013, 108(11):2259-2263.
54.	Zagouri F, Sergentanis TN, Azim H Jr, et al. Aromatase inhibitors in male breast cancer:a pooled analysis. Breast Cancer Res Treat, 2015, 151(1):141-147.
55.	Gucalp A, Tolaney S, Isakoff SJ, et al. Phase Ⅱ trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res, 2013, 19(19):5505-5512.
56.	Di Leo A, Jerusalem G, Petruzelka L, et al. Final overall survival:fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst, 2014, 106(1):djt337.
57.	Zagouri F, Sergentanis TN, Chrysikos D, et al. Fulvestrant and male breast cancer:a pooled analysis. Breast Cancer Res Treat, 2015, 149(1):269-275.
58.	Hayashi H, Kimura M, Yoshimoto N, et al. A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment. Breast Cancer, 2009, 16(2):136-140.

1. Ruddy KJ, Winer EP. Male breast cancer:risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol, 2013, 24(6):1434-1443.
2. Ly D, Forman D, Ferlay J, et al. An international comparison of male and female breast cancer incidence rates. Int J Cancer, 2013, 132(8):1918-1926.
3. 程兆明, 蒋光愉, 曾颖, 等. 217077名妇女乳腺癌筛查结果分析.中华普通外科杂志, 2016, 31(4):328-332.
4. Korde LA, Zujewski JA, Kamin L, et al. Multidisciplinary meeting on male breast cancer:summary and research recommendations. J Clin Oncol, 2010, 28(12):2114-2122.
5. Serarslan A, Gursel B, Okumus NO, et al. Male breast cancer:20 years experience of a tertiary hospital from the middle black sea region of Turkey. Asian Pac J Cancer Prev, 2015, 16(15):6673-6679.
6. Chavez-Macgregor M, Clarke CA, Lichtensztajn D, et al. Male breast cancer according to tumor subtype and race a population-based study. Cancer, 2013, 119(9):1611-1617.
7. Dawood S. Updates from the 2014 San antonio breast cancer symposium. Indian J Med Paediatr Oncol, 2015, 36(1):66-70.
8. Johansson I, Killander F, Linderholm B, et al. Molecular profiling of male breast cancer-lost in translation. Int J Biochem Cell Biol, 2014, 53:526-535.
9. Korde LA, Zujewski JA, Kamin L, et al. Multidisciplinary meeting on male breast cancer:summary and research recommmendations. J Clin Oncol, 2010, 28(12):2114-2122.
10. De Juan I, Palanca S, Domenech A, et al. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study. Fam Cancer, 2015, 14(4):505-513.
11. Silvestri V, Barrowdale D, Mulligan AM, et al. Male breast cancer in BRCA1 and BRCA2 mutation carriers:pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res, 2016, 18(1):15.
12. Brinton LA, Cook MB, McCormack V, et al. Anthropometric and hormonal risk factors for male breast cancer:male breast cancer pooling project results. J Natl Cancer Inst, 2014, 106(3):djt465.
13. Humphries MP, Jordan VC, Speirs V. Obesity and male breast cancer:provocative parallels. BMC Med, 2015, 13:134.
14. Brinton LA, Key TJ, Kolonel LN, et al. Prediagnostic sex steroid hormones in relation to male breast cancer risk. J Clin Oncol, 2015, 33(18):2041-2050.
15. Grundy A, Harris SA, Demers PA, et al. Occupational exposure to magnetic fields and breast cancer among Canadian men. Cancer Med, 2016, 5(3):586-596.
16. Morrogh M, King TA. The significance of nipple discharge of the male breast. Breast J, 2009, 15(6):632-638.
17. Gradishar WJ, Anderson BO, Balassanian R, et al. Breast cancer version 2.2015. J Natl Compr Canc Netw, 2015, 13(4):448-475.
18. Graspari E, Ricci A, Liberto V, et al. An unusual case of mammary paget's disease diagnosed using dynamic contrast-enhanced MRI. Case Rep Radiol, 2013, 2013:206235.
19. 刘新丽, 刘芳芳, 郑屹, 等.男性乳腺癌临床病理特征及预后分析.中国肿瘤临床, 2014, 41(23):1521-1526.
20. 王翔宇, 方仪, 杨雪, 等.男性乳腺癌的临床病理特征及生存分析.临床肿瘤学杂志, 2016, 21(4):340-343.
21. Nilsson C, Koliadi A, Johansson I, et al. High proliferation is associated with inferior outcome in male breast cancer patients. Mod Pathol, 2013, 26(1):87-94.
22. 马家芳, 乔昱, 丁丽, 等.男性乳腺癌患者临床病理特征及诊治分析.中华老年医学杂志, 2015, 34(7):790-792.
23. Leone JP, Leone J, Zwenger AO, et al. Prognostic significance of tumor subtypes in male breast cancer:a population-based study. Breast Cancer Res Treat, 2015, 152(3):601-609.
24. 张志刚, 郭团魁, 周玉峰.男性乳腺癌临床病例分析.疾病监测与控制, 2016, 10(4):336-338.
25. 韩娜, 王晓稼. 29例男性乳腺癌临床分析.分子诊断与治疗杂志, 2016, 8(1):23-26.
26. Abreu MH, Afonso N, Abreu PH, et al. Male breast cancer:looking for better prognostic subgroups. Breast, 2016, 26:18-24.
27. Zhou FF, Xia LP, Guo GF, et al. Changes in therapeutic strategies in Chinese male patients with breast cancer:40 years of experience in a single institute. Breast, 2010, 19(6):450-455.
28. 李林, 朱明智, 邱新光.男性乳腺癌前哨淋巴结活检11例分析.国际外科学杂志, 2015, 42(3):171-173.
29. Maráz R, Boross G, Pap-Szekeres J, et al. The role of sentinel node biopsy in male breast cancer. Breast Cancer, 2016, 23(1):85-91.
30. Gnerlich JL, Deshpande AD, Jeffe DB, et al. Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration. Ann Surg Oncol, 2011, 18(17):1837-1844.
31. Zaenger D, Rabatic BM, Dasher B, et al. Is breast conserving therapy a safe modality for early-stage male breast cancer. Clin Breast Cancer, 2016, 16(2):101-104.
32. Bratman SV, Kapp DS, Horst KC. Evolving trends in the initial locoregional management of male breast cancer. Breast, 2012, 21(3):296-302.
33. Atalay C, Kanlioz M, Altinok M. Prognostic factors affecting survival in male breast cancer. J Exp Clin Cancer Res, 2003, 22(1):29-33.
34. Yu E, Suzuki H, Younus J, et al. The impact of post-mastectomy radiation therapy on male breast cancer patients-a case series. Int J Radiat Oncol Biol Phys, 2012, 82(2):696-700.
35. Cutuli B, Le-Nir CC, Serin D, et al. Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Crit Rev Oncol Hematol, 2010, 73(3):246-254.
36. Giordano SH, Perkins GH, Broglio K, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer, 2005, 104(11):2359-2364.
37. Sun B, Zhang LN, Zhang J, et al. The prognostic value of clinical and pathologic features in nonmetastatic operable male breast cancer. Asian J Androl, 2016, 18(1):90-95.
38. Untch M, Gerber B, Harbeck N, et al. 13th st. Gallen international breast cancer conference 2013:primary therapy of early breast cancer evidence, controversies, consensus-opinion of a german team of experts (zurich 2013). Breast Care (Basel), 2013, 8(3):221-229.
39. 王丽娜, 严颖, 李惠平, 等.男性乳腺癌25例的临床病理特征及生存分析.癌症进展, 2014, 12(1):64-69.
40. Sousa B, Moser E, Cardoso F. An update on male breast cancer and future directions for research and treatment. Eur J Pharmacol, 2013, 717(1-3):71-83.
41. Zhou FF, Xia LP, Wang X, et al. Analysis of prognostic factors in male breast cancer:a report of 72 cases from a single institution. Chin J Cancer, 2010, 29(2):184-188.
42. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med, 2002, 137(8):678-687.
43. Xu S, Yang Y, Tao W, et al. Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. Breast Cancer Res Treat, 2012, 136(2):495-502.
44. Wenhui Z, Shuo L, Dabei T, et al. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment. Eur J Endocrinol, 2014, 171(4):527-533.
45. Eggemann H, Ignatov A, Smith BJ, et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat, 2013, 137(2):465-470.
46. Pemmaraju N, Munsell MF, Hortobagyi GN, et al. Retrospective review of male breast cancer patients:analysis of tamoxifen-related side-effects. Ann Oncol, 2012, 23(6):1471-1474.
47. 刘朋, 王芙荣, 纪立伟, 等. 212例他莫昔芬不良反应回顾性分析.中国药物应用与监测, 2011, 8(6):366-368.
48. Di Lauro L, Vici P, Del Medico P, et al. Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. Breast Cancer Res Treat, 2013, 141(1):119-123.
49. Doyen J, Italiano A, Largillier R, et al. Aromatase inhibition in male breast cancer patients:biological and clinical implications. Ann Oncol, 2010, 21(6):1243-1245.
50. 陈峰, 邱丽贞.芳香化酶抑制剂在早期男性乳腺癌治疗中的生物学效益及临床意义.中华医学杂志, 2014, 94(4):273-275.
51. Pritchard KI, Shepherd LE, Chapman J, et al. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women:NCIC CTG Ma.14. J Clin Oncol, 2011, 29(29):3869-3876.
52. Kuba S, Ishida M, Oikawa M, et al. Aromatase inhibitors with or without luteinizing hormone-releasing hormone agonist for metastatic male breast cancer:report of four cases and review of the literature. Breast Cancer, 2016, [Epub ahead of print].
53. Zagouri F, Sergentanis TN, Koutoulidis V, et al. Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer:a case series. Br J Cancer, 2013, 108(11):2259-2263.
54. Zagouri F, Sergentanis TN, Azim H Jr, et al. Aromatase inhibitors in male breast cancer:a pooled analysis. Breast Cancer Res Treat, 2015, 151(1):141-147.
55. Gucalp A, Tolaney S, Isakoff SJ, et al. Phase Ⅱ trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res, 2013, 19(19):5505-5512.
56. Di Leo A, Jerusalem G, Petruzelka L, et al. Final overall survival:fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst, 2014, 106(1):djt337.
57. Zagouri F, Sergentanis TN, Chrysikos D, et al. Fulvestrant and male breast cancer:a pooled analysis. Breast Cancer Res Treat, 2015, 149(1):269-275.
58. Hayashi H, Kimura M, Yoshimoto N, et al. A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment. Breast Cancer, 2009, 16(2):136-140.

Previous Article
Reconsideration of Posthepatectomy Liver Failure
Next Article
胰十二指肠切除术后胰肠吻合口假性囊肿自发性破裂1例报道

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research Progress of Male Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content